retatrutide parkinson's disease clinical trial Study in Parkinson of Exercise Phase 3 (SPARX 3) Eli Lilly infiltrates anti-obesity market
Description
This requires a paradigm shift in the development of education, research, and protocols on dietary supplementation in conjunction with GLP-1RAs
Therapeutic experience is limited in people aged 75 years or older, but dose adjustment is not necessary
This was an increase of 88.2% or 1.9-fold higher than the rate in 2023, which was 0.5%
Consider DEXA scans for baseline and follow-up in those with osteopenia or osteoporosis
doi: 10.2337/DB13-1440
10 This is especially important as GLP-1 receptor agonists confer multiple benefits for patients with diabetes, including better glucose control and weight loss
